



00270

PATENT TRADEMARK OFFICE

COPY



UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/700,329	02/08/2001	Philip C. Gevas	ACG2AUSA	4824

7590

03/28/2002

Howson and Howson
PO Box 457
Spring House Corporate Center
Spring House, PA 19477



EXAMINER

BORIN, MICHAEL L

ART UNIT	PAPER NUMBER
----------	--------------

1631

DATE MAILED: 03/28/2002

RECEIVED
APR 13 2002
TECH CENTER 1600/2900
DUE 4-28-02

Please find below and/or attached an Office communication concerning this application or proceeding:

RECEIVED

MAY 03 2002

TECH CENTER 1600/2900

RECEIVED

SEP 12 2003

TECH CENTER 1600/2900



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/700329	02/08/2001	Gevas et al	ACG2AUSA

RECEIVED

MAY 03 2002

TECH CENTER 1600/2900

EXAMINER	
Michael Borin	
ART UNIT	PAPER NUMBER
1631	13

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotides and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). See 37 CFR 1.821 (d). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is also requested to provide SEQ ID Nos for peptide sequences in specification and claims.

Any inquiry concerning this communication should be directed to Examiner M.L. Borin, Art Unit 1631 whose telephone number is (703) 305-4506.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

MICHAEL BORIN, PH.D
PRIMARY EXAMINER

Application No.: 09/700329

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). A paper copy is in the file but is not in accordance with new Sequence Listing Rules.
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



00270

PATENT TRADEMARK OFFICE

SEQUENCE LISTING

<110> Gevas, Philip
Grimes, Stephen
Karr, Stephen
Michaeli, Dov
Watson, Susan

<120> Prevention and Treatment of Hypergastrinemia

<130> ACG2USA

<140> US 09/700,329

<141> 2001-02-08

<150> PCT/US99/10751

<151> 1999-05-14

<150> 60/085,714

<151> 1998-05-15

<160> 9

<170> PatentIn version 3.0

<210> 1

<211> 9

<212> PRT

<213> human gastrin peptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> pyroglutamic acid

<400> 1

Glu Gly Pro Trp Leu Glu Glu Glu Glu
1 5

<210> 2

<211> 12

<212> PRT

<213> human gastrin peptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> pyroglutamic acid

<400> 2

Glu Leu Gly Pro Gln Gly Arg Pro Pro Pro Pro Cys
1 5 10

RECEIVED
TECH CENTER 1600/2900
02 APR 25 PM 2:33

RECEIVED

MAY 03 2002

TECH CENTER 1600/2900

RECEIVED

SEP 12 2003

TECH CENTER 1600/2900

<210> 3
 <211> 7
 <212> PRT
 <213> human or synthetic peptide

<400> 3

Ser Ser Pro Pro Pro Pro Cys
 1 5

<210> 4
 <211> 7
 <212> PRT
 <213> human gastrin peptide

<220>
 <221> MOD_RES
 <222> (7)..(7)
 <223> AMIDATION

<400> 4

Glu Ala Tyr Gly Trp Met Asp
 1 5

<210> 5
 <211> 12
 <212> PRT
 <213> human gastrin peptide

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> pyroglutamic acid

<400> 5

Glu Gly Pro Trp Leu Glu Arg Pro Pro Pro Pro Cys
 1 5 10

<210> 6
 <211> 11
 <212> PRT
 <213> human gastrin peptide

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> pyroglutamic acid

<400> 6

Glu Gly Pro Trp Leu Arg Pro Pro Pro Pro Cys
 1 5 10

<210> 7
 <211> 10
 <212> PRT
 <213> human gastrin peptide

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> pyroglutamic acid

<400> 7

Glu Gly Pro Trp Arg Pro Pro Pro Pro Cys
 1 5 10

<210> 8
 <211> 12
 <212> PRT
 <213> rat gastrin peptide

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> pyroglutamic acid

<400> 8

Glu Arg Pro Pro Leu Glu Arg Pro Pro Pro Pro Cys
 1 5 10

<210> 9
 <211> 15
 <212> PRT
 <213> human gastrin peptide

<400> 9

Asp Pro Ser Lys Lys Gln Gly Pro Trp Leu Pro Pro Pro Pro Cys
 1 5 10 15